Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Markers (Meissner's Corpuscles and Epidermal Nerve Fiber Density) and Sensory Testing (Quantitative Sensory and Gait Testing): A Single Center Feasibility Study

Launched by M.D. ANDERSON CANCER CENTER · Nov 2, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment method called neuromodulation to see if it can help reduce pain caused by chemotherapy-induced peripheral neuropathy (CIPN). CIPN can occur after certain cancer treatments and often leads to discomfort or pain in the feet and legs. Researchers are looking to find out if this new approach can improve patients' symptoms and overall quality of life.

To participate in this study, patients need to be between 18 and 85 years old and must have been diagnosed with CIPN due to specific chemotherapy drugs. It's important that participants can understand and agree to join the study by signing a consent form. Those with recent substance abuse issues, cognitive problems, or other types of nerve pain won't be eligible. If you join the trial, you can expect to undergo some tests to assess your nerve health and pain levels, helping researchers understand how well the treatment works. This study is currently recruiting participants at the Pain Management Center at MD Anderson Cancer Center.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Ability to understand and the willingness to sign a written informed consent document
• • Patients diagnosed with CIPN lower extremity due to either vinca alkaloids, taxanes, bortezomib, thalidomide, platinum-based compounds
• • Patients seen at Pain Management Center at MD Anderson Cancer Center
• • Patient ages greater or equal to 18 years but less than or equal to 85 years
• • Exclusion Criteria
• • Patients with cognitive dysfunction
• • Patient with recent history (\<6 months) of drug or alcohol abuse
• • Patients with open skin lesion or undergoing antibiotic therapy for local for systemic infection
• • Patients with painful diabetic peripheral neuropathy or preexisting peripheral neuropathy